As of April 1, 2026, the Avacta Group PLC (AVCT.L) share price is 63.80p, marking a 0.79% increase from the previous close. The company currently holds a market capitalization of approximately £281.87 million, with shares trading within a 52-week range of 26.00p to 84.00p. The stock saw significant volatility in late March 2026 following the announcement of a successfully completed £10 million oversubscribed fundraise, which secured the company’s cash runway into early 2027. This capital injection is specifically earmarked for the acceleration of the pre|CISION® platform clinical trials, including the much-anticipated Phase 1a data for AVA6103.
2026 Share Price Performance Summary
The first quarter of 2026 has been a period of intense activity for AVCT.L. After starting the year at 58.00p, the share price hit a peak of 75.00p in mid-March before stabilizing in the low 60s following the most recent equity placing.
As of early April, the stock’s year-to-date movement is +11.21%, outperforming several peers in the FTSE AIM 100 index. Average daily trading volume has remained high, approximately 1.75 million shares, indicating strong institutional and retail interest as the company hits key clinical milestones.
The £10 Million Equity Fundraise
On March 27, 2026, Avacta announced the results of an oversubscribed fundraise, raising £10 million through a placing of 15.9 million new shares at 63p each. This pricing represented a minimal discount to the market rate, signaling strong investor confidence in the company’s valuation.
The participation of non-executive directors Richard Hughes and David Bryant, who collectively contributed £550,000, served as a significant “buy signal” for the market. The proceeds are designated to fund the Phase 1 trial of AVA6103, a peptide drug conjugate designed to treat solid tumors with high precision and minimal systemic toxicity.
Clinical Progress: The pre|CISION® Platform
The core driver of Avacta’s long-term share value is its proprietary pre|CISION® platform. This technology modifies chemotherapy drugs so they only become active inside the tumor microenvironment, potentially reducing the side effects associated with traditional cancer treatments.
AVA6103 Phase 1 Trial: Opened in March 2026, this study is currently evaluating the safety and efficacy of the conjugate in patients with various solid tumors.
Faridoxorubicin (AVA6000): Following positive updates in late 2025 regarding tumor shrinkage in salivary gland cancer, the company is preparing for Phase 2 readiness in mid-2026.
CSO Appointment: In February 2026, Avacta appointed a new Chief Scientific Officer to oversee the expansion of the pipeline into new therapeutic areas, including lung and soft tissue sarcomas.
Financial Health and Cash Runway
With the completion of the March fundraise, Avacta has effectively addressed concerns regarding its immediate liquidity. The company’s current cash position is expected to support all ongoing clinical operations into Q1 2027.
Management has stated that this runway is sufficient to reach initial data readouts for AVA6103. By securing this funding early, the company has avoided the “cash-crunch” narratives that often affect pre-revenue biotech firms, allowing the share price to react more directly to clinical successes rather than financing fears.
Practical Information and Planning
Investors looking to trade or monitor AVCT.L in 2026 should be aware of the following structural and practical details.
Stock Exchange: London Stock Exchange (LSE), AIM Market.
Ticker Symbol: AVCT (GBX – Pence Sterling).
Key Reporting Dates: The 2025/26 Annual Results are expected in late May 2026, with an interim update scheduled for September 2026.
Major Holders: Institutional presence remains high, including significant positions held by Lombard Odier and other specialist life science funds.
Investment Tips: Monitor “Reach” and “RNS” (Regulatory News Service) announcements on the London Stock Exchange website for real-time updates on clinical trial dosing and results.
FAQs
What is the current Avacta (AVCT) share price?
As of April 1, 2026, the share price is 63.80p.
How much did Avacta raise in March 2026?
The company raised £10 million through an oversubscribed equity placing at 63p per share.
What is AVA6103?
AVA6103 is Avacta’s second clinical-stage peptide drug conjugate, which entered Phase 1 trials in March 2026 to target solid tumors.
Is Avacta listed on the NASDAQ?
No, Avacta Group PLC is listed on the AIM market of the London Stock Exchange under the ticker AVCT.
When will the next clinical data be released?
Initial Phase 1a data for AVA6103 is expected in early 2027, though interim “safety” updates are likely in late 2026.
Who is the current broker for Avacta?
Zeus Capital currently serves as the broker and bookrunner for Avacta’s equity fundraises.
What is the pre|CISION® platform?
It is a proprietary technology that uses a specific enzyme (FAP) found in tumors to activate chemotherapy drugs only where they are needed.
Did any directors buy shares recently?
Yes, in March 2026, two non-executive directors invested a combined £550,000 into the company as part of the £10m fundraise.
What is Avacta’s market cap?
As of April 2026, the market capitalization is approximately £281.87 million.
How has the share price performed in 2026 so far?
The share price is up approximately 11.21% year-to-date as of April 1, 2026.
What was the 52-week high for AVCT?
The 52-week high for the stock was 84.00p.
For More business Related insights click on :
B&M: The Ultimate Guide to UK’s Leading Variety Value Retailer
iPhone 17 Pro: The Definitive Guide to Apple’s 2026 Flagship
To read more ,New Castle Reporter